NEW YORK – QIMR Berghofer Medical Research Institute's spin-out company GenomiQa announced on Tuesday that it has partnered with Icon Group to validate its whole-genome analysis platform CapeDx.
The pilot study will enroll up to 15 patients and will be conducted in collaboration with the Icon Cancer Centre Wesley in Auchenflower, Australia. The CapeDx platform will help personalize a patient's cancer treatment through hereditary whole-genome sequencing and tumor sequencing. The analysis provided by the platform will be used to match patients to the most suitable cancer treatment, which can include both approved drugs and experimental drugs accessible through clinical trials.
GenomiQa CEO Colin Albert said the validation study was a major step towards rolling out the company’s precision analytics platform more widely.
This pilot project is backed by the Commonwealth Department of Industry, Science, Energy and Resources through the Entrepreneurs' Programme and the QIMR Berghofer Medical Research Institute, which has provided nearly A$500,000 (US$369,000) in matched funding.